top of page


After holding the hands of hundreds of children suffering from congenital heart disease, the founder of our technology felt there had to be a better way to provide care to children without having to rely on the highly restrictive MRI. Moreover, she still wanted to provide doctors with complete and full information that they need to monitor the heart state and make a confident diagnosis. It was this immediate need for change and compassion that eventually led to the idea of the VMS and the creation of Ventripoint.


Ventripoint Diagnostics Ltd. (TSXV:VPT, OTCQB:VPTDF) is dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians,  and most importantly improves the clinical experience for our youngest to oldest patient.   


Innovation starts with big hearts.

We strongly believe our greatest medical achievements rested upon human compassion and dedication.  Thus, we encourage our team to draw upon the heartfelt dedication that drove our founder to find a more accessible approach to monitoring a pediatric patient's heart as a springboard to all  product development.   


We design with the patient and the user in mind.

​When designing our products, we believe that we must always come up with design solutions that both improve the patient's clinical experience and empower the clinician.  Further to this thinking, we think that we  should not lose sight of the fact that we strongly believe in doing our part to promote a strong universal healthcare system. We owe it to our dedicated and caring healthcare providers to develop cost effective medical devices that can reach clinics, and support  the most vulnerable and underserviced populations.


Quality is not about checking the boxes.

We believe in the highest degree of quality for every product we design and develop. We have placed great emphasis on creating and fostering a culture focused on quality.   


We rise together and fall together. 


We believe that our success is a culmination of every team member's success and we each share in all failures.  Our failures make us as strong a team as our successes.  

In keeping with this thinking, we aim to provide our team members with all the opportunities to grow, learn and be inspired.  We also encourage a balance between work and life.  We work hard, but have some fun along the way.  


Hugh MacNaught - Interim CEO, Director

Mr. MacNaught is a Fortune 100 trained executive with thirty years experience in the innovation, development, financing, and commercialisation of medical and life science technologies. He has worked in roles ranging from product development and manufacturing to finance, business development and executive management. His background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging. His familiarity with research translation and technology development within early stage companies includes several years as a venture capitalist and founding, leading and financing technology ventures.

During the past decade Hugh has provided guidance to university spin-outs, corporate venturing initiatives and served as a business mentor at several Canadian universities. He has served as a director for corporations and not-for-profit agencies, including serving as the Audit Chair for Genome Prairie. He sat on the Technology Commercialization Committee for the Alberta Heritage Foundation for Medical Research, and is currently a member of the Core Evaluation Team for the GAPP Program at Genome Canada.

Dr. George Adams - Chairman, Member of Nominating & Corporate Governance & Audit Committees

Dr. Adams is a scientist, a serial entrepreneur and a financier. His previous position was CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010. He was Chairman of Sernova Corp (TSXV:SVA) and President and CEO of the UT Innovations Foundation from 1999 until 2004. Prior to this, he held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross, Blood Transfusion Service. He has been instrumental in founding over 30 companies who have raised $100 million and has been a Director of 10 venture capital funds and 10 start-up companies. .Dr. Adams was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009. Dr Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence.

Robert Hodgkinson - Director

Mr. Hodgkinson has over 40 years of experience in public and venture capital markets.  He has raised $150M+ of capital for numerous companies and is an experienced corporate director, senior executive and adviser.  He has been instrumental in successful merger and acquisitions in oil and gas transactions totaling $500M+ and has acted as a principal and agent in corporate structuring/restructuring.


Fiona Fitzgerald  - Director

Ms. Fitzgerald is the current National Zone Leader for Cytiva Life Science and accounts for all the commercial products in Canada. She has over two decades of experience working with GE in Canada and made the transition to Cytiva in March 2020. Ms. Fitzgerald has sat on multiple Government of Canada Federal Committees including NSERC's CREATE program, which she later chaired, and several NSERC Centre of Excellence Evaluation committees. She currently holds three board memberships in CIMTEC, MDCC, and is on the Advisory Board for the Centre of Bioengineering and Biotechnology in Waterloo University. Ms. Firzgerald seeks to further develop the Life Sciences industry in Canada and will be focusing her efforts in the growth and development of Ventripoint.

Randy AuCoin - Director

Randy AuCoin is currently the President and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer. Mr. AuCoin has raised over $50 million of venture capital and has had senior roles in Quinton Electrophysiology Corporation, DICOMIT, VisualSonics Inc., and Imagistx Inc. He has extensive experience in fund raising, sales and marketing, operations, and finance. Mr. AuCoin aims to guide Ventripoint towards becoming the standard-of-care for cardiac ultrasound diagnostics. 


bottom of page